United Therapeutics announced that its Board of Directors has approved a new share repurchase program, authorizing the company to buy back up to $2.0 billion of its common stock. The authorization reflects the company's confidence in its financial position and commitment to delivering shareholder value.
Key Details
- Authorization Amount: Up to $2.0 billion of the company's common stock.
- Effective Period: The program is authorized for a one-year period, ending on October 21, 2027.
- Implementation Methods: Repurchases can be made through various methods, including accelerated share repurchase (ASR) programs, open market transactions, or privately negotiated deals at the company's discretion.
- Additional Context: This new program is separate from an ongoing ASR transaction initiated in September 2026 under a prior authorization, which is expected to be completed in Q4 2026.